Bio-Techne Corporation (TECH) |
| 58.66 1.13 (1.96%) 04-14 16:00 |
| Open: | 57.98 |
| High: | 60.44 |
| Low: | 57.71 |
| Volume: | 2,491,499 |
| Market Cap: | 9,178(M) |
| PE Ratio: | 110.68 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 70.59 |
| Resistance 1: | 60.44 |
| Pivot price: | 53.99 |
| Support 1: | 52.91 |
| Support 2: | 48.25 |
| 52w High: | 72.16 |
| 52w Low: | 46.01 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
| EPS | 0.530 |
| Book Value | 12.900 |
| PEG Ratio | 0.00 |
| Gross Profit | 5.175 |
| Profit Margin (%) | 6.67 |
| Operating Margin (%) | 19.67 |
| Return on Assets (ttm) | 6.5 |
| Return on Equity (ttm) | 4.0 |
Tue, 14 Apr 2026
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results - Bitget
Tue, 14 Apr 2026
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results - Yahoo Finance
Tue, 14 Apr 2026
Bio-Techne Corp (NASDAQ:TECH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mon, 13 Apr 2026
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Mon, 13 Apr 2026
TD Cowen Adjusts Price Target on Bio-Techne to $65 From $80, Maintains Buy Rating - marketscreener.com
Mon, 13 Apr 2026
Massachusetts Financial Services Co. MA Has $235.99 Million Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |